Investment Thesis
Autonomix Medical is a pre-revenue company with accelerating losses (-46.5% YoY), burning $12.3M annually in operating cash while holding only $7.0M in cash—providing less than 7 months of runway. Without imminent revenue generation or capital infusion, the company faces existential risk despite a clean balance sheet.
Strengths
- Strong immediate liquidity with $7.0M cash covering 92% of assets and 4.45x current ratio
- Conservative capital structure with only 0.25x debt-to-equity and $5.9M positive equity
- Minimal capital expenditure ($10K) suggests product may be near commercialization phase
Risks
- Zero revenue with no visible commercialization traction in medical device sector requiring lengthy FDA approval cycles
- Accelerating losses: net income declined 46.5% YoY, indicating burn rate is worsening not improving
- Critical cash runway of less than 7 months at current $12.3M annual operating burn rate, creating imminent dilution or insolvency risk
- Medical device regulatory and market risks combined with unproven commercialization capability
- No insider activity in 90 days suggests limited management confidence in near-term prospects
Key Metrics to Watch
- Quarterly revenue recognition and commercialization timeline
- Monthly operating cash burn rate and cash balance trajectory
- Announcements of capital raises, debt financing, or strategic partnerships
- Product regulatory approval status and customer acquisition metrics
Financial Metrics
Revenue
0.0
Net Income
-16.7M
EPS (Diluted)
$-0.74
Free Cash Flow
-12.3M
Total Assets
7.6M
Cash
7.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-283.5%
ROA
-219.9%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
4.45x
Quick Ratio
4.45x
Debt/Equity
0.25x
Debt/Assets
22.4%
Interest Coverage
-170.34x
Long-term Debt
1.5M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-06-06T07:43:39.795800 |
Data as of: 2026-03-31 |
Powered by Claude AI